GM17547
LCL from B-Lymphocyte
Description:
BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases |
Class |
X Chromosome Markers |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
White
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase,Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
Gene |
BTK |
Chromosomal Location |
Xq22.1 |
Allelic Variant 1 |
300300.0035; AGAMMAGLOBULINEMIA |
Identified Mutation |
CYS506ARG; In a patient with X-linked agammaglobulinemia, Hagemann et al. (1994) identified a T-to-C transition at position 1648 in exon 15, resulting in a substitution of arginine for cysteine-506 in the middle of the kinase domain. Whether this residue is directly involved in catalytic activity or substrate recognition is not clear.
|
Remarks |
Clinically affected; at age 4 patient had recurrent pyogenic infections; IgG<50mg/dl; IgM<30mg/dl; IgA<20mg/dl; B lymphocytes express IgD and IgM; the cells synthesize small amounts of intracellular IgD, but there is no evidence of secretion; maternal uncle also has agammaglobulinemia; mother is GM17566; donor subject has T-to-C transition at nucleotide 1648 in exon 15 of the BTK gene (1648T>C) resulting in a substitution of arginine for cysteine at codon 506 in the middle of the kinase domain [Cys506Arg (C506R)] |
Tao L, Boyd M, Gonye G, Malone B, Schwaber J, BTK mutations in patients with X-linked agammaglobulinemia: lack of correlation between presence of peripheral B lymphocytes and specific mutations. Hum Mutat16(6):528-9 2000 |
PubMed ID: 11102984 |
|
Schwaber J, Chen RH, Premature termination of variable gene rearrangement in B lymphocytes from X-linked agammaglobulinemia. J Clin Invest81(6):2004-9 1988 |
PubMed ID: 2838527 |
|
Schwaber J, Koenig N, Girard J, Correction of the molecular defect in B lymphocytes from X-linked agammaglobulinemia by cell fusion. J Clin Invest82(4):1471-6 1988 |
PubMed ID: 3139715 |
|
Schwaber J, Payne J, Chen R, B lymphocytes from X-linked agammaglobulinemia. Delayed expression of light chain and demonstration of Lyonization in carriers. J Clin Invest81(2):514-22 1988 |
PubMed ID: 3123521 |
|
Schwaber J, Lazarus H, Rosen FS, Restricted classes of immunoglobulin produced by a lymphoid cell line from a patient with agammaglobulinemia. Proc Natl Acad Sci U S A75(5):2421-3 1978 |
PubMed ID: 209464 |
|
Schwaber JF, Rosen FS, Induction of human immunoglobulin synthesis and secretion in somatic cell hybrids of mouse myeloma and human B lymphocytes from patients with agammaglobulinemia. J Exp Med148(4):974-86 1978 |
PubMed ID: 100574 |
dbSNP |
dbSNP ID: 21125 |
Gene Cards |
BTK |
Gene Ontology |
GO:0004713 protein-tyrosine kinase activity |
|
GO:0005524 ATP binding |
|
GO:0005737 cytoplasm |
|
GO:0006468 protein amino acid phosphorylation |
|
GO:0007242 intracellular signaling cascade |
|
GO:0007498 mesoderm development |
|
GO:0008624 induction of apoptosis by extracellular signals |
|
GO:0016740 transferase activity |
NCBI Gene |
Gene ID:695 |
NCBI GTR |
300300 BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK |
OMIM |
300300 BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK |
Omim Description |
AGAMMAGLOBULINEMIA TYROSINE KINASE; ATK |
|
AGAMMAGLOBULINEMIA, X-LINKED, TYPE I, INCLUDED; AGMX1, INCLUDED |
|
B-CELL PROGENITOR KINASE; BPKAGAMMAGLOBULINEMIA, X-LINKED, INCLUDED; XLA, INCLUDED |
|
BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK |
|
BRUTON TYPE AGAMMAGLOBULINEMIA, INCLUDED |
|
HYPOGAMMAGLOBULINEMIA, X-LINKED, INCLUDED |
|
IMMUNODEFICIENCY 1, INCLUDED; IMD1, INCLUDED |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|